Sponsor Pipeline

Dana-Farber Cancer Institute Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
155
Active Trials
63
Recruiting
2
Phase 3
10
Disease Areas
5
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-02 NCT07601100
Phase 1b/2: Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant…
Primary endpoint(s) modified
2026-06-02 NCT07601100
Phase 1b/2: Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant…
Trial arms changed: 2 -> 6
2026-05-23 NCT05225428
Video Education With Result Dependent dIsclosure
date change Primary completion pushed: 2026-04-30 -> 2026-08-30
2026-05-23 NCT05225428
Video Education With Result Dependent dIsclosure
date change Completion pushed: 2026-09-01 -> 2026-10-01
2026-05-15 NCT04789486
Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and…
date change Completion pushed: 2028-09-10 -> 2030-04-10
New Trial Filings, Last 30 Days
First PostedTrialPhaseStatus
2026-06-03 NCT07624513 Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction… Phase 3 Not Yet Recruiting
2026-05-22 NCT07601100 Phase 1b/2: Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant… Phase 1/2 Not Yet Recruiting
Active Trials by Phase
Phase 4
1
Phase 3
2
Phase 2
46
Phase 1/2
10
Phase 1
24
Early Phase 1
3
Not specified
69
Active Trials — top 25 of 155
NCT IDTitleConditionStatus
Phase 4
NCT07426484 Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy Cutaneous Squamous Cell Carcinoma Not Yet Recruiting
Phase 3
NCT03020030 Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents Acute Lymphoblastic Leukemia, Pediatric Active, Not Recruiting
NCT07624513 Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction… Multiple Myeloma Not Yet Recruiting
Phase 2
NCT06366347 ALPINE: Maintenance Letrozole/Abemaciclib Endometrial Cancer Recruiting
NCT07397611 Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC Renal Cell Carcinoma Recruiting
NCT07465276 Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC Head and Neck Squamous Cell Carcinoma (HNSCC) Recruiting
NCT04620187 Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas Salivary Gland Cancer Recruiting
NCT07123649 Individualizing Approaches to Surveillance Mammography in Older Breast Cancer Survivors… Breast Cancer Recruiting
NCT04893109 ATEMPT 2.0: Adjuvant T-DM1 vs TH Breast Cancer Recruiting
NCT03310879 Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations… Cancer Recruiting
NCT04468061 Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC Breast Cancer Recruiting
NCT04434040 Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) Breast Cancer Recruiting
NCT07434843 PH 2 Pemigatinib in SDH-deficient GIST SDH Gene Mutation Recruiting
NCT07467772 Ph 2 Elacestrant in ER Positive Uterine Sarcomas Uterine Sarcoma Recruiting
NCT05922761 BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP) Bronchiolitis Obliterans Syndrome Recruiting
NCT00165256 Wide Excision Alone as Treatment for Ductal Carcinoma in Situ of The Breast Ductal Carcinoma in Situ of the Breast Active, Not Recruiting
NCT03668340 AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine… Uterine Cancer Active, Not Recruiting
NCT02653755 The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II… Breast Cancer Radiation Active, Not Recruiting
NCT06001762 TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer Breast Cancer Active, Not Recruiting
NCT03333616 Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Genitourinary Cancer Active, Not Recruiting
NCT02648997 An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants… Meningiomas Active, Not Recruiting
NCT02919683 Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the… Head and Neck Cancer Active, Not Recruiting
NCT02876302 Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative… Inflammatory Breast Cancer (IBC) Active, Not Recruiting
NCT01574274 SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and… Acute Lymphoblastic Leukemia Active, Not Recruiting
NCT04938232 Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL Hodgkin Lymphoma Active, Not Recruiting
View all 155 active Dana-Farber Cancer Institute trials with filters →
Disease Areas
Get alerts when Dana-Farber Cancer Institute's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free